Imatinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
* Date of FDA Approval (Expiration): 2001 (2015) | * Date of FDA Approval (Expiration): 2001 (2015) | ||
* 2009 Global Sales: $3.9 Billion | * 2009 Global Sales: $3.9 Billion | ||
* Importance: It is one of the best selling [[cancer]] drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. Although now considered hyperbole, TIME magazine declared that Gleevec was "converting a fatal cancer into a manageable chronic condition." Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.< | * Importance: It is one of the best selling [[cancer]] drugs of all time. It was the drug to be approved from the tyrosine kinase inhibitor class of drugs. Although now considered hyperbole, TIME magazine declared that Gleevec was "converting a fatal cancer into a manageable chronic condition." Has generated significant controversy due to its nearly $65,000 per year cost at a time when global health care budgets are being stretched thin.<ref>A Conversation With Brian J. Druker, M.D., Researcher Behind the Drug Gleevec by Claudia Dreifus, The New York Times, November 2, 2009</ref> | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||
